ArticleMedicine2025
Causal effect of gut microbiota and its metabolites on cerebral small vessel disease: A multivariable Mendelian randomization analysis.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between Blood-Brain Barrier Disruption and Gut Microbiota Dysbiosis in Parkinson's Disease.Cellular and molecular neurobiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence suggests a strong relationship between cerebral small vessel disease (CSVD), gut microbiota (GM), and their secreted metabolites. The major subtypes of CSVD include lacunar stroke, cerebral microbleeds, perivascular spaces (PVSs), and white matter hyperintensity (WMH) volume. However, their causal relationship remains unknown. A 2-sample Mendelian randomization (MR) analysis was undertaken on summarized data from genome-wide association studies. Univariable MR and multivariable MR were used to find the possible causal link between CSVD, GM, and their metabolites. The causal association was determined through the inverse variance weighted, weighted median, maximum likelihood, MR-Egger regression, and MR-PRESSO approaches. Multiple sensitivity tests were employed to evaluate the presence of horizontal pleiotropy and heterogeneity. A reverse MR analysis determined the potential for reverse causality. Finally, enrichment analyses were carried out to elucidate relevant biological functions. Overall, 1505 host single-nucleotide polymorphisms related to 119 GM features and 1873 related to 81 GM-derived metabolites (GMDMs) were identified as exposure variables. Two intestinal bacteria were linked with raised likelihood of WMH volume, 1 with cerebral microbleeds, 2 with lacunar stroke, and 7 with PVSs. However, 3 bacterial species were correlated with decreased WMH volume risk, 2 to lacunar stroke, and 8 to PVSs. Moreover, the possible causal link between 28 GMDMs and CSVD was observed. Enrichment analysis revealed the crucial involvement of multiple key regulatory pathways. This study provided new insights into gut biomarkers and specialized prevention and therapy for CSVD by demonstrating evidence of the causal link between GM, GMDMs, and CSVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.